Jianfeng Group Pro 2017-024 (Announcement on Authorizing Chairman to Decide to Entrust Financial Management)
Release time:
2020-08-05
Securities Abbreviations: Jianfeng Group Securities Code: 600668 No.: Pro 2017-024
Bond Abbreviations: 13 Peak 01 Bond Code: 122227
Bond Abbreviations: 13 Peak 02 Bond Code: 122344
Announcement of Zhejiang Jianfeng Group Co., Ltd.
on Authorizing the Chairman to Decide to Entrust Financial Management
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents .
Important Note:
● Entrusted Financial Management Amount: Authorizes the Chairman of the Board to exercise the decision-making power of entrusted financial management not exceeding RMB 2 .9 billion Yuan. Funds within this amount can be used in a rolling manner, but the total amount of entrusted financial management remaining at any time point shall not exceed RMB 0.2 billion Yuan .
● Type of entrusted wealth management investment: Select varieties with high security, good liquidity and low risk to carry out entrusted wealth management business.
● Duration of entrusted financial management: The duration of each entrusted financial management shall not exceed 12 months.
1. Overview
Basic Information of (I)
1 . Principle: The company will take "Standardize operation, prevent risks, invest prudently and maintain and increase value" as the principle.
2 , varieties: choose high security, good liquidity, low risk varieties to carry out entrusted financial management business.
3 , funds: phased idle own funds.
4 , Authorized Amount and Term: Authorized Chairman of the Board of Directors to exercise the decision-making power of entrusted financial management not exceeding RMB 2 .9 billion, within which funds can be used on a rolling basis, but the total balance of entrusted financial management existing at any point in time shall not exceed RMB 0.2 billion. The term of each entrusted financial management shall not exceed 12 months. The authorization period shall be valid for 3 years from the date of approval by the board of directors of the company. The specific investment activities are organized and implemented by the Company's Finance Department.
5 , Implementation: Authorize the chairman of the board to decide on matters related to entrusted financial investment within the above amount, including but not limited to: selecting qualified professional financial institutions, selecting specific types of entrusted financial products, specifying the amount and duration of entrusted financial management, signing relevant contracts and agreements, etc.
(II) the approval procedures to be performed within the company
on August 25, 2017 , the 15th meeting of the 9th board of directors held by the company deliberated and passed the proposal on authorizing the chairman of the company to use idle self-owned funds for entrusted financial management. Voting result: 9 votes in favor, 0 votes against and 0 abstentions.
2. main content(I) entrusted funds source:
phased idle self-owned funds .
The impact of (II) on the company1
, the company uses phased idle self-owned funds for entrusted financial management, which is implemented on the premise of ensuring the company's daily operation and capital safety, and does not affect the company's daily capital turnover, Does not affect the normal development of the company's business operations.
2. By conducting moderate and low-risk financial product investment business, we can improve the efficiency of capital use, obtain certain investment benefits, and seek more investment returns for the company's shareholders.
(III) Risk Control AnalysisThe company strictly follows the "Entrusted Financial Management System" approval and implementation procedures to ensure the effective development and standardized operation of entrusted financial management and other investment businesses. However, as the financial market is greatly affected by the economic environment, it is not ruled out that investment businesses such as investment and wealth management will be affected by market fluctuations. The company will take the following measures:
(1
) The company will clearly assign special personnel to be responsible for such investment matters Related work: the chairman of the company exercises such investment decision-making power and signs relevant contract documents, the company's financial officer is responsible for organizing the implementation, and the specific operations.
(2) The company's finance department is responsible for timely analysis and tracking of the investment direction of financial products and the progress of investment projects. If the evaluation finds that there are conditions that may affect the company's capital security or affect the normal capital flow demand, corresponding preservation or redemption measures will be taken in a timely manner to control investment risks.
(3) The audit department of the company is responsible for auditing and supervising various investments, regularly auditing and verifying the progress, profit and loss, risk control, etc. of entrusted financial management, and evaluating the possible risks and benefits of various entrusted financial management according to the principle of prudence, and reporting to the audit committee of the board of directors.
(4) The office of the board of directors of the company fulfills its information disclosure obligations in accordance with the relevant regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange.
Opinions of (IV) Independent DirectorsThe independent directors of the company issued independent opinions on the resolution, and believed that: the approval procedures of the proposal comply with laws and regulations and the relevant provisions of the company's Articles of Association; the company complies with national laws and regulations and Under the premise of ensuring the safety of investment funds, carrying out entrusted wealth management business with its own funds is conducive to improving the efficiency of fund use and obtaining certain benefits, it is in the interests of the Company and all shareholders, and there is no harm to the interests of the Company and all shareholders, especially the small and medium shareholders.
3. As of the date of this announcement, the company's accumulated entrusted financial management
| serial number | trustee | financial management product type | amount (ten thousand yuan) | start date | due date | Amount Recovered as of Announcement Date (RMB 10,000) |
Income as of Announcement Date (RMB 10,000) |
| 1 | Guangfa Bank Jinhua Branch | Salary Increase 16 5876 RMB Structured Deposit Product | 5,000.00 | 2017/4/6 | 2017/7/5 | 5,000.00 | 51.16 |
| 2 | Bohai Bank Jinhua Branch | Bohai Bank S17180 Structured Deposit Financial Product | 3,000.00 | 2017/5/17 | 2017/6/19 | 3,000.00 | 10.58 |
| 3 | Bohai Bank Jinhua Branch | Bohai Bank S17265 Structural deposit wealth management product | 3,000.00 | 2017/6/23 | 2017/7/27 | 3,000.00 | 12.30 |
| 4 | Guangfa Bank Jinhua Branch | salary and salary increase No. 16 J0253 RMB structured deposit product | 4,000.00 | 2017/7/6 | 2017/10/9 | ||
| 5 | CGB Jinhua Branch | Salary Increase No. 16 J352 RMB Structured Deposit Product | 4,000.00 | 2017/7/28 | 2017/11/13 |
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
August 29, 2017
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page